Akeso Spells Out the Survival Data Behind Its Keytruda Beat

Akeso and partner Summit Therapeutics, having claimed a win over Merck's Keytruda at the start of September, are now detailing the overall survival data from the head-to-head trial of their PD-1xVEGF bispecific antibody; Summit shares last closed at 17.55, up 3.24% on the day on 11 September 2026.

Akeso is putting numbers behind the claim it and partner Summit Therapeutics made at the start of September: that their PD-1xVEGF bispecific antibody beat Merck's Keytruda in a head-to-head trial. The companies are now detailing the overall survival data from that study, according to Endpoints News, and are positioning the readout as the latest addition to a growing body of evidence behind the class.

That sequencing matters. The initial September claim was the announcement; the survival detail is the evidence. In oncology, the gap between the two is where valuations get made and unmade, because overall survival — how much longer patients actually live — is the endpoint regulators weigh most heavily and the one oncologists trust when deciding what to prescribe.

Why a bispecific aimed at PD-1 and VEGF is different

Keytruda works by blocking PD-1, a brake on the immune system that tumors exploit to avoid attack. Release the brake and T cells can recognise and kill cancer cells. It is the most commercially successful mechanism in modern oncology, and for a decade the way to improve on it has been to add something to it rather than replace it.

The PD-1xVEGF bispecific approach tries to do both jobs with one molecule. VEGF — vascular endothelial growth factor — is the signal tumors use to grow their own blood supply, and blocking it starves the tumor while also, in theory, making the surrounding tissue more hospitable to immune cells. Putting the two targets into a single antibody is an attempt to get combination-level benefit without combination-level dosing, cost or toxicity management.

The scientific question has never been whether that story is plausible. It is whether a bispecific can beat Keytruda outright in a randomized, head-to-head trial rather than merely look good against historical comparisons. That is the test Akeso and Summit say they have passed, and the survival data now being detailed is the substance of the claim.

What overall survival adds that response rates do not

Cancer trials generate several kinds of good news, and they are not equal. A higher response rate says tumors shrank. Progression-free survival says the disease took longer to get worse. Overall survival says patients lived longer. Only the last one is immune to the argument that an imaging endpoint flattered the drug without changing a patient's life.

It is also the hardest to produce. Survival data takes time to mature, requires enough deaths in both arms for the statistics to mean anything, and in diseases where patients go on to receive several later lines of treatment, the effect of the first drug can be diluted by everything that follows. A survival advantage over an active comparator as entrenched as Keytruda — not over placebo, not over chemotherapy alone — is the version of the result that carries the most weight with regulators, payers and prescribers alike.

That is the frame investors should apply as the detail emerges. The questions worth asking of any such dataset are the same ones an oncology reviewer asks: how mature is the follow-up, how wide are the confidence intervals, was the comparison pre-specified, and does the safety profile leave room for the drug to be used in the settings where Keytruda is used today.

The stock reaction so far, and what Merck has at stake

Summit Therapeutics (ticker: SMMT) last closed at 17.55, a gain of 3.24% on the session, having finished the prior day at 17.00 and traded in a range of 17.14 to 17.70. Those are the most recent prices, as of the close on Friday, 11 September 2026; the market is shut.

Merck (ticker: MRK) last closed at 143.93, down 0.54% on the day from a prior close of 144.71, with a session range of 143.68 to 145.90. That is a mild drift lower on a day when the broad market was firm: the S&P 500 tracker (SPY) closed at $764.29, up 0.85%, the Nasdaq 100 tracker (QQQ) at $714.88, up 0.87%, and the Dow tracker (DIA) at $525.79, up 0.97%.

The asymmetry between the two stocks is the whole story of this trade. For Summit, a single asset carries most of the company's value, so incremental evidence moves the shares in a way that nothing at Merck's scale can match. For Merck, Keytruda is the largest revenue line in the business and the anchor of its oncology franchise — but any competitive threat plays out over years of trial readouts, regulatory reviews, launch sequencing and payer negotiations, not over a single session's price action. A sub-1% drift in a large-cap pharmaceutical stock on a broadly positive day is not a verdict. It is a shrug with a slight frown.

The parts of this that are still open

Three things will determine whether the September claim becomes a commercial fact.

• The full data in public. Detail released by companies is not the same as a peer-reviewed presentation with the curves, the hazard ratios and the subgroup breakdowns on a conference screen. The gap between a press claim and a plenary session has embarrassed oncology developers before.
• Regulatory reception. A head-to-head survival win is the strongest card a challenger can hold, but reviewers will look at trial geography, patient selection and whether the control arm was treated the way it would be treated in the markets where approval is sought.
• Breadth. Keytruda's strength is not one indication; it is dozens. Beating it in one setting opens a door. Displacing it across the franchise requires repeating the result in tumor types with different biology and different standards of care.

How the class fits the wider oncology trade

The PD-1xVEGF field has drawn heavy interest precisely because it is the first credible attempt in years to take share from checkpoint inhibition rather than layer onto it, and because the economics of doing so are enormous. Every large pharmaceutical company with an oncology franchise is watching the same datasets, and licensing activity in the space has been shaped by them.

For investors, the practical read is narrower than the excitement. Akeso's disclosure of survival detail raises the evidentiary bar for anyone else claiming the mechanism works, and it raises it for Merck's own defensive programs. But it does not, on its own, change what Keytruda earns next quarter or next year. What to watch next is the venue and format in which the full survival data is presented, and whether the effect holds up when independent eyes get the curves rather than the summary.

Key facts

• Summit Therapeutics (SMMT) last close: 17.55, +3.24% — as of 20:00 GMT, 11 Sep 2026
• Merck (MRK) last close: 143.93, -0.54% — as of 20:00 GMT, 11 Sep 2026
• Mechanism: PD-1xVEGF bispecific antibody, tested head-to-head against Keytruda
• Timing: Win claimed at the start of September; survival data now being detailed

Frequently asked questions

What did Akeso and Summit Therapeutics announce?

At the start of September the two partners claimed their PD-1xVEGF bispecific antibody had beaten Merck's Keytruda in a head-to-head trial. Akeso is now detailing the overall survival data behind that claim, which the companies present as further evidence supporting the drug class. The full dataset detail is what turns the initial announcement into assessable evidence.

What is a PD-1xVEGF bispecific antibody?

It is a single engineered antibody that hits two targets at once. PD-1 is an immune checkpoint that tumors use to switch off T cells; blocking it releases that brake. VEGF is the signal tumors use to build their own blood supply; blocking that starves the tumor and may make the surrounding tissue easier for immune cells to enter. One molecule, two mechanisms.

Why does overall survival matter more than other trial endpoints?

Overall survival measures whether patients live longer. Response rate only shows tumors shrank, and progression-free survival only shows the disease took longer to worsen. Regulators, payers and oncologists weight survival most heavily because it cannot be flattered by imaging measurements. It is also the slowest and hardest endpoint to produce, which is why a survival win carries weight.

How did Summit Therapeutics shares perform?

Summit Therapeutics closed at 17.55 on Friday, 11 September 2026, up 3.24% from a prior close of 17.00, having traded between 17.14 and 17.70 during the session. That was the last trade before the market closed. For a company whose value is concentrated in a single asset, data disclosures move the shares more than they would a diversified drugmaker.

What does this mean for Merck's Keytruda franchise?

Keytruda is Merck's largest revenue line and the anchor of its oncology business, so a credible head-to-head challenger is strategically significant. But displacement would take years of further readouts, regulatory reviews and payer decisions across dozens of indications. Merck shares closed at 143.93 on 11 September 2026, down 0.54% on a day when broad indices rose — a mild reaction, not a verdict.

What should investors watch next?

Three things: whether the full survival curves, hazard ratios and subgroup data are presented at a medical conference or in a peer-reviewed journal rather than described in company statements; how regulators view the trial's design, geography and control arm; and whether the result can be repeated in other tumor types, since Keytruda's strength lies in its breadth of approved indications.

Sources

• Akeso details survival win for its PD-1xVEGF drug versus Keytruda — Endpoints News

Photo: https://kaboompics.com/ · Pexels Licence — source